Ken Griffin Prelude Therapeutics Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 200 shares of PRLD stock, worth $1,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Previous 700 71.43%

Holding current value

$1,032

Previous $2,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.68 - $4.84 $175,633 - $317,189	-65,535 Reduced 68.75%	29,795 $141,000
Q4 2023 Feb 14, 2024	SELL	$1.69 - $4.37 $346,062 - $894,849	-204,771 Reduced 68.23%	95,330 $407,000
Q3 2023 Nov 14, 2023	BUY	$2.74 - $4.79 $721,255 - $1.26 Million	263,232 Added 713.97%	300,101 $927,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $164,067 - $299,376	36,869 New	36,869 $165,000
Q4 2022 Feb 14, 2023	BUY	$4.61 - $8.5 $11,515 - $21,233	2,498 Added 15.88%	18,232 $110,000

Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $469,445 - $828,100	-93,889 Reduced 85.65%	15,734 $104,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $234,900 - $443,373	58,725 Added 115.38%	109,623 $572,000
Q1 2022 May 16, 2022	SELL	$6.9 - $13.22 $604,453 - $1.16 Million	-87,602 Reduced 63.25%	50,898 $352,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $1.47 Million - $3.94 Million	124,005 Added 855.5%	138,500 $1.72 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $38.65 $128,925 - $193,288	-5,001 Reduced 25.65%	14,495 $453,000
Q1 2021 May 17, 2021	BUY	$39.27 - $91.68 $765,607 - $1.79 Million	19,496 New	19,496 $845,000
Q4 2020 Feb 16, 2021	SELL	$28.81 - $88.94 $3.2 Million - $9.86 Million	-110,915 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$26.2 - $30.13 $2.91 Million - $3.34 Million	110,915 New	110,915 $3.34 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

34.2M

Call Options Held

200

Put Options Held

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $188M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account